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D
iabetes is a chronic disease that af-
fects 20 million Americans (1)
and is characterized by serious,
costly, and often fatal complications. The
totalcostofdiagnoseddiabetesintheU.S.
in 2007 was estimated to be $174 billion
(2). To prevent or delay costly diabetes
complications and to enable people with
diabetes to lead healthy, productive lives,
appropriate medical care based on current
standards of practice, self-management
education, and medication and supplies
must be available to everyone with diabe-
tes. This paper is based on technical re-
views titled “Diabetes Self-Management
Education” (3) and “National Standards
for Diabetes Self-Management Education
Programs” (4).
The goal of medical care for people
withdiabetesistooptimizeglycemiccon-
trol and minimize complications. The Di-
abetes Control and Complications Trial
(DCCT)demonstratedthattreatmentthat
maintains blood glucose levels near nor-
mal in type 1 diabetes delays the onset
and reduces the progression of microvas-
cularcomplications.TheU.K.Prospective
Diabetes Study (UKPDS) documented
that optimal glycemic control can also
beneﬁt most individuals with type 2 dia-
betes.Toachieveoptimalglucosecontrol,
the person with diabetes must be able to
access health care providers who have ex-
pertise in the ﬁeld of diabetes. Treatment
plans must also include self-management
training and tools, regular and timely lab-
oratory evaluations, medical nutrition
therapy, appropriately prescribed medi-
cation(s), and regular self-monitoring of
blood glucose levels. The American Dia-
betes Association position statement
“Standards of Medical Care in Diabetes”
outlinesappropriatemedicalcareforpeo-
ple with diabetes (5).
An integral component of diabetes
care is self-management education (inpa-
tient and/or outpatient) delivered by an
interdisciplinary team. Self-management
traininghelpspeoplewithdiabetesadjust
their daily regimen to improve glycemic
control. Diabetes self-management edu-
cation teaches individuals with diabetes
to assess the interplay among medical nu-
trition therapy, physical activity, emo-
tional/physical stress, and medications,
and then to respond appropriately and
continuallytothosefactorstoachieveand
maintain optimal glucose control.
Today, self-management education is
understood to be such a critical part of
diabetes care that medical treatment of
diabetes without systematic self-manage-
ment education is regarded as inadequate.
The “National Standards for Diabetes Self-
Management Education” establish spe-
ciﬁc criteria against which diabetes
education programs can be measured,
andaqualityassuranceprogramhasbeen
developed and subsequently revised (6).
Treatments and therapies that im-
prove glycemic control and reduce the
complications of diabetes will also signif-
icantlyreducehealthcarecosts(7,8).Nu-
merous studies have demonstrated that
self-management education leads to re-
ductions in the costs associated with all
types of diabetes. Participants in self-
management education programs have
been found to have decreased lower-
extremity amputation rates, reduced
medication costs, and fewer emergency
room visits and hospitalizations.
To achieve optimal glycemic control,
thus achieving long-term reduction in
health care costs, individuals with diabe-
tes must have access to the integral com-
ponents of diabetes care, such as health
care visits, diabetes supplies, self-
management education, and diabetes
medications.Assuch,insurersmustreim-
burse for diabetes-related medical treat-
ment as well as for self-management
education programs that have met ac-
cepted standards, such as the American
DiabetesAssociation’sNationalStandards
for Diabetes Self-Management Education.
Furthermore, third-party payers must
also reimburse for medications and sup-
plies related to the daily care of diabetes.
These same standards should also apply
toorganizationsthatpurchasehealthcare
beneﬁts for their members or employees,
aswellasmanagedcareorganizationsthat
provide services to participants.
It is recognized that the use of formu-
laries, prior authorization, competitive
bidding, and related provisions (hereafter
referred to as “controls”) can manage pro-
vider practices and costs to the potential
beneﬁt of payors and patients. Social Se-
curity Act Title XIX, section 1927, states
that excluded medications should not
have “a signiﬁcant clinically meaningful
therapeutic advantage in terms of safety,
effectiveness or clinical outcomes of such
treatment of such population.” A variety
of laws, regulations, and executive orders
also provide guidance on the use of such
controls to oversee the purchase and use
of durable medical equipment (hereafter
referred to as “equipment”) and single-
usemedicalsupplies(hereafterreferredto
as “supplies”) associated with the man-
agement of diabetes.
Certain principles should guide the
creation and enforcement of controls in
order to insure that they meet the com-
prehensivemedicalneedsofpeopleliving
with diabetes. A wide array of medica-
tions and supplies are correlated with
improved glycemic outcomes and a re-
duction in the risk of diabetes-related
complications. Because no single diabe-
tes treatment regimen is appropriate for
all people with diabetes, providers and
patients should have access to a broad
array of medications and supplies to de-
velop an effective treatment modality.
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nizes that there may be a number of
medications and/or supplies within any
given class. As such, any controls
should ensure that all classes of anti-
diabetic agents with unique mecha-
nisms of action are available to facilitate
achieving glycemic goals to reduce the
riskofcomplications.Similarissuesoper-
ate in the management of lipid disorders,
hypertension, and other cardiovascular
risk factors, as well as for other diabetes
complications.Furthermore,anycontrols
should ensure that all classes of equip-
ment and supplies designed for use with
such equipment are available to facilitate
achieving glycemic goals to reduce the
risk of complications. It is important to
note that medical advances are rapidly
changing the landscape of diabetes
medications and supplies. To ensure
that patients with diabetes have access
to beneﬁcial updates in treatment mo-
dalities, systems of controls must em-
ploy efﬁcient mechanisms through
which to introduce and approve new
products.
Though it can seem appropriate for
controls to restrict certain items in chronic
disease management, particularly with a
complex disorder such as diabetes, it
should be recognized that adherence is a
major barrier to achieving targets. Any
controls should take into account the
huge mental and physical burden that in-
tensive disease management exerts upon
patientswithdiabetes.Protectionsshould
ensure that patients with diabetes can
readilycomplywiththerapyinthewidely
variable circumstances encountered in
daily life. These protections should guar-
antee access to an acceptable range and all
classes of antidiabetic medications, equip-
ment, and supplies. Furthermore, fair and
reasonable appeals processes should
ensure that diabetic patients and their
medical care practitioners can obtain
medications, equipment, and supplies that
are not contained within existent controls.
Diabetes management needs individ-
ualization in order for patients to reach
glycemic targets. Because there is diver-
sity in the manifestations of the disease
and in the impact of other medical condi-
tions upon diabetes, it is common that
practitioners will need to uniquely tailor
treatment for their patients. To reach dia-
betes treatment goals, practitioners
should have access to all classes of antidi-
abetic medications, equipment, and sup-
plies without undue controls. Without
appropriate safeguards, these controls
could constitute an obstruction of effec-
tive care.
The value of self-management edu-
cation and provision of diabetes sup-
plies has been acknowledged by the
passage of the Balanced Budget Act of
1997 (9) and by stated medical policy
on both diabetes education and medical
nutrition therapy.
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